Darwinweg 24
Leiden 2333 CR
Netherlands
31 71 524 7400
https://www.pharming.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 332
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Sijmen de Vries M.B.A., M.D. | Pres, CEO & Exec. Director | 1,18M | S.O. | 1959 |
Mr. Jeroen Wakkerman | Chief Financial Officer | S.O. | S.O. | 1969 |
Ms. Mireille Sanders M.Sc. | Chief Operations Officer | S.O. | S.O. | 1968 |
Susanne Embleton | Investor Relations Mang. | S.O. | S.O. | S.O. |
Mr. Ruud Van Outersterp | Chief Ethics & Compliance Officer | S.O. | S.O. | 1964 |
Dr. Anurag Relan M.D., MPH | Chief Medical Officer | S.O. | S.O. | 1972 |
Mr. Stephen Toor | Chief Commercial Officer & GM Americas | S.O. | S.O. | 1971 |
Dr. Alexander Breidenbach M.B.A. | Chief Bus. Officer | S.O. | S.O. | S.O. |
Dr. Bruno M. L. Giannetti | Consultant | S.O. | S.O. | 1952 |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
L’ISS Governance QualityScore de Pharming Group N.V. en date du 1 octobre 2023 est 4. Les scores principaux sont Audit : 7; Société : 1; Droits des actionnaires : 4; Compensation : 8.